OPKO Health, Inc.: Hyperparathyroidism, Secondary trials
The registry lists 12 Hyperparathyroidism, Secondary studies with OPKO Health, Inc. as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 4Phase 2 4Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsRecruitingNCT07494045Phase 2
- Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismTerminatedNCT05543928Phase 3Results posted
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedNCT02282813Phase 3Results posted
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01704079Phase 3Results posted
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01651000Phase 3Results posted
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)CompletedNCT01219855Phase 2/3Results posted
- Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy SubjectsCompletedNCT03660800Phase 1
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic AcidCompletedNCT02274623Phase 1
- Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)WithdrawnNCT01453634Phase 2
- Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCompletedNCT00888069Phase 1
- Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)CompletedNCT00792857Phase 1
- Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney DiseaseCompletedNCT00742716Phase 2